The quest for developing new treatments from imaging techniques: Promises, problems and future potential

Michael J. Minzenberg, Cameron S Carter

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Drug discovery and development in psychiatry is beset by many challenges, both those which are associated with the development process in general (and affecting all of medicine) and others, which are unique to psychiatry. Due to these factors, marginal progress has been achieved in the past as many features of serious mental illness remain untouched by existing treatments. Arguably, the most important of these drug targets is cognitive dysfunction, which strongly predicts clinical outcome in a number of major neuropsychiatric conditions. Therefore, a critical need exists for progress in the characterization of this and other targets for drug discovery and development. A key area, which is already showing promise, is the use of non-invasive functional neuroimaging to investigate both cognitive dysfunction and its remediation with novel agents. In this article, the authors describe the paradigmatic case of cognitive dysfunction in schizophrenia, and the prospects for using functional magnetic resonance imaging (fMRI) to investigate the effects of agents targeting cognition. The authors observe a number of advantages of this approach over other methodologies, as well as some significant issues to be resolved in the application of this technology. The authors propose that pharmaco-fMRI is emerging as a major tool to enhance the drug development process in order to bring truly novel treatments to patients with a range of neuropsychiatric disorders.

Original languageEnglish (US)
Pages (from-to)1029-1033
Number of pages5
JournalExpert Opinion on Drug Discovery
Volume2
Issue number8
DOIs
StatePublished - Aug 2007

Fingerprint

Drug Discovery
Psychiatry
Magnetic Resonance Imaging
Functional Neuroimaging
Pharmaceutical Preparations
Cognition
Schizophrenia
Therapeutics
Medicine
Technology
Cognitive Dysfunction

Keywords

  • Biomarker
  • Cognition
  • Drug development
  • Functional magnetic resonance imaging
  • Pharmacology
  • Psychiatry

ASJC Scopus subject areas

  • Drug Discovery

Cite this

The quest for developing new treatments from imaging techniques : Promises, problems and future potential. / Minzenberg, Michael J.; Carter, Cameron S.

In: Expert Opinion on Drug Discovery, Vol. 2, No. 8, 08.2007, p. 1029-1033.

Research output: Contribution to journalArticle

@article{e9820315ef424b25b115c21e6e4d935b,
title = "The quest for developing new treatments from imaging techniques: Promises, problems and future potential",
abstract = "Drug discovery and development in psychiatry is beset by many challenges, both those which are associated with the development process in general (and affecting all of medicine) and others, which are unique to psychiatry. Due to these factors, marginal progress has been achieved in the past as many features of serious mental illness remain untouched by existing treatments. Arguably, the most important of these drug targets is cognitive dysfunction, which strongly predicts clinical outcome in a number of major neuropsychiatric conditions. Therefore, a critical need exists for progress in the characterization of this and other targets for drug discovery and development. A key area, which is already showing promise, is the use of non-invasive functional neuroimaging to investigate both cognitive dysfunction and its remediation with novel agents. In this article, the authors describe the paradigmatic case of cognitive dysfunction in schizophrenia, and the prospects for using functional magnetic resonance imaging (fMRI) to investigate the effects of agents targeting cognition. The authors observe a number of advantages of this approach over other methodologies, as well as some significant issues to be resolved in the application of this technology. The authors propose that pharmaco-fMRI is emerging as a major tool to enhance the drug development process in order to bring truly novel treatments to patients with a range of neuropsychiatric disorders.",
keywords = "Biomarker, Cognition, Drug development, Functional magnetic resonance imaging, Pharmacology, Psychiatry",
author = "Minzenberg, {Michael J.} and Carter, {Cameron S}",
year = "2007",
month = "8",
doi = "10.1517/17460441.2.8.1029",
language = "English (US)",
volume = "2",
pages = "1029--1033",
journal = "Expert Opinion on Drug Discovery",
issn = "1746-0441",
publisher = "Informa Healthcare",
number = "8",

}

TY - JOUR

T1 - The quest for developing new treatments from imaging techniques

T2 - Promises, problems and future potential

AU - Minzenberg, Michael J.

AU - Carter, Cameron S

PY - 2007/8

Y1 - 2007/8

N2 - Drug discovery and development in psychiatry is beset by many challenges, both those which are associated with the development process in general (and affecting all of medicine) and others, which are unique to psychiatry. Due to these factors, marginal progress has been achieved in the past as many features of serious mental illness remain untouched by existing treatments. Arguably, the most important of these drug targets is cognitive dysfunction, which strongly predicts clinical outcome in a number of major neuropsychiatric conditions. Therefore, a critical need exists for progress in the characterization of this and other targets for drug discovery and development. A key area, which is already showing promise, is the use of non-invasive functional neuroimaging to investigate both cognitive dysfunction and its remediation with novel agents. In this article, the authors describe the paradigmatic case of cognitive dysfunction in schizophrenia, and the prospects for using functional magnetic resonance imaging (fMRI) to investigate the effects of agents targeting cognition. The authors observe a number of advantages of this approach over other methodologies, as well as some significant issues to be resolved in the application of this technology. The authors propose that pharmaco-fMRI is emerging as a major tool to enhance the drug development process in order to bring truly novel treatments to patients with a range of neuropsychiatric disorders.

AB - Drug discovery and development in psychiatry is beset by many challenges, both those which are associated with the development process in general (and affecting all of medicine) and others, which are unique to psychiatry. Due to these factors, marginal progress has been achieved in the past as many features of serious mental illness remain untouched by existing treatments. Arguably, the most important of these drug targets is cognitive dysfunction, which strongly predicts clinical outcome in a number of major neuropsychiatric conditions. Therefore, a critical need exists for progress in the characterization of this and other targets for drug discovery and development. A key area, which is already showing promise, is the use of non-invasive functional neuroimaging to investigate both cognitive dysfunction and its remediation with novel agents. In this article, the authors describe the paradigmatic case of cognitive dysfunction in schizophrenia, and the prospects for using functional magnetic resonance imaging (fMRI) to investigate the effects of agents targeting cognition. The authors observe a number of advantages of this approach over other methodologies, as well as some significant issues to be resolved in the application of this technology. The authors propose that pharmaco-fMRI is emerging as a major tool to enhance the drug development process in order to bring truly novel treatments to patients with a range of neuropsychiatric disorders.

KW - Biomarker

KW - Cognition

KW - Drug development

KW - Functional magnetic resonance imaging

KW - Pharmacology

KW - Psychiatry

UR - http://www.scopus.com/inward/record.url?scp=34548442585&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548442585&partnerID=8YFLogxK

U2 - 10.1517/17460441.2.8.1029

DO - 10.1517/17460441.2.8.1029

M3 - Article

C2 - 23484869

AN - SCOPUS:34548442585

VL - 2

SP - 1029

EP - 1033

JO - Expert Opinion on Drug Discovery

JF - Expert Opinion on Drug Discovery

SN - 1746-0441

IS - 8

ER -